NCR1 and neoplasm: More recently, trifunctional NK cell engagers targeting two activating receptors, NKp46 and CD16, on NK cells and a tumor antigen (CD19, CD20, or EGFR) on cancer cells were generated by Prof. Vivier and his colleagues (111).